EXCLUSIVE: GT Biopharma Reports Progresses Phase 1 Trial Of Lead Drug Candidate For Blood Cancers - GT Biopharma (NASDAQ:GTBP)

GT Biopharma, a clinical-stage immuno-oncology company using its TriKE natural killer cell engager platform, said AI tools rolled out internally have improved discovery and drug engineering productivity. The company plans to advance lead programs GTB-3650 and GTB-5550 through Phase 1 studies this year and use AI for candidate selection, molecular design, and structural modeling. Shares were up 0.38% to $0.48 premarket, per Benzinga Pro.

Halliburton secured a contract to construct wells for Eni's Cronos project, an ultra-deepwater development off Cyprus. The deal highlights Halliburton's role in the East Mediterranean's energy sector.

Michael Burry, known for his 2007 real estate market bet, has short positions in Oracle (ORCL), Palantir (PLTR), and Nebius (NBIS). He reduced bets against NVDA and PLTR. Burry's options suggest an AI crash by year-end, but Nvidia's GPU deals and Hugging Face acquisition indicate strong AI demand. Palantir's government contracts may boost revenue.

Jefferies launched healthcare REIT coverage, favoring senior housing due to demographics and limited supply. It initiated Janus Living (Buy, $36 target), Welltower (Buy, $275 target), and Ventas (Buy, $102 target) with Buy ratings, citing quality and growth. Healthpeak and Healthcare Realty Hold were rated neutral.

Halliburton has won a multi-year contract with Eni to provide well services for the Cronos gas development offshore Cyprus. The contract covers exploration and development wells in Block 6 of Cyprus’ Exclusive Economic Zone. Halliburton will offer integrated services, including drilling, well construction, and completions, using its LOGIX technologies. The contract expands Halliburton’s presence in the Eastern Mediterranean, though the value and duration were not disclosed.

Berenberg upgraded Eli Lilly to buy, raising its price target to $1,400, citing strong performance in the obesity market and potential upside in its GLP-1 drug pipeline. Shares have risen 52% over the past year, and the analyst expects further growth. Eli Lilly makes Mounjaro and Zepbound, with additional drugs in development. 27 of 34 analysts recommend buying the stock. Shares gained over 1% in premarket trading.